📰 Progression Scale News
Progression Scale News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Progression Scale. Real-time updates on events, politics, business and more.
April 26, 2024
Antibiotic treatment of adults hospitalized with moderate COVID-19 is associated with clinical deterioration, despite the drugs being given to over 40% of patients, according to new research being presented at this year's ESCMID Global Congress (formerly ECCMID) in Barcelona, Spain (27-30 April)
February 20, 2023
This platform randomized clinical trial examines the effectiveness ivermectin at a targeted dose of 600 μg/kg daily compared with placebo for the treatment of e
January 11, 2023
Compared with placebo, convalescent plasma with neutralizinganti-SARS-CoV-2 antibodies showed no improvement in hospitalized patients with COVID-19 at day 14, according to a study published in CHEST.
December 20, 2022
Researchers assessed the impact of ivermectin on the duration of sustained recovery among coronavirus disease 2019 (COVID-19) outpatients.
October 21, 2022
This randomized clinical trial compares the efficacy of ivermectin vs placebo in shortening symptom duration among adult outpatients in the US with symptomatic
July 13, 2022
Phase 3 trial demonstrated a reduction in SARS-CoV-2 viral load in high-risk COVID-19 patients by 94% and 99% within 24 and 48 hours of treatment, respectively Median time to a negative PCR
February 9, 2022
In a first, a novel nitric oxide nasal spray was launched in India for treating Covid-19 among adults who are at high risk of progressing to severe stages of the viral disease.
February 7, 2022
Researchers in the United Kingdom have conducted an observational cohort study on hospitalized patients and have found that the degree of severity of acute coronavirus disease 2019 (COVID-19) predicts the occurrence of chronic cerebrovascular impairment. The study further suggests that the levels of cerebrovascular impairment are associated with worse cognitive, mental, and physical well-being.
January 20, 2022
SAN DIEGO , Jan. 19, 2022 -- Sorrento Therapeutics , Inc. (Nasdaq: SRNE, "Sorrento") today announced that the US Phase 2 study ( www.ClinicalTrials.gov NCT04906694) with intranasal COVI-DROPS treatment in COVID-19 outpatients has completed enrollment.
November 4, 2021
This case-control study explores the association between vaccination with mRNA COVID-19 vaccines and hospitalization for COVID-19, and, among patients hospitali